With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Denmark’s suspension of AZD1222 following blood clots heaps even more pressure on Astra’s US study.
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.